Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Feniralstat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 20/20 | 0.95 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Feniralstat SCHEMBL21145564 | 0.98 | KLKB1 (1.00) | KLKB1CYP3A4CYP2C8CYP2C9 | |
| Feniralstat SCHEMBL23456766 | 0.97 | KLKB1 (0.98) | KLKB1CYP3A4CYP2C8CYP2C9 | |
| Feniralstat SCHEMBL29619265 | 0.97 | KLKB1 (0.98) | KLKB1CYP3A4CYP2C8CYP2C9 | |
| Feniralstat SCHEMBL23456763 | 0.95 | KLKB1 (0.94) | KLKB1CYP3A4CYP2C8CYP2C9 | |
| Feniralstat SCHEMBL23456746 | 0.95 | KLKB1 (0.94) | KLKB1CYP3A4CYP2C8CYP2C9 | |
| Feniralstat SCHEMBL22491847 | 0.93 | KLKB1 (0.90) | KLKB1CYP3A4CYP2C8CYP2C9 | |
| Feniralstat SCHEMBL28433437 | 0.91 | KLKB1 (0.87) | KLKB1CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL21985907 | 0.91 | KLKB1 (0.87) | KLKB1CYP3A4CYP2C8CYP2C9 | |
| Sebetralstat SCHEMBL22495443 | 0.90 | KLKB1 (0.95) | KLKB1CYP3A4CYP2C8CYP2C9 | |
| Feniralstat SCHEMBL22491814 | 0.90 | KLKB1 (0.85) | KLKB1CYP3A4CYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203012-A1 | SOLID FORMS OF A PLASMA KALLIKREIN INHIBITOR AND SALTS THEREOF | CROWE DAVID MALCOLM (GB) | 2023-06-29 | — | — | US | disclosed |
| US-11584735-B2 | Solid forms of a plasma kallikrein inhibitor and salts thereof | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-20210171496-A1 | SOLID FORMS OF A PLASMA KALLIKREIN INHIBITOR AND SALTS THEREOF | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-06-10 | — | — | US | disclosed |
| CN-111433197-A | Solid forms of plasma kallikrein inhibitors and salts thereof | 卡尔维斯塔制药有限公司 | 2020-07-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584735-B2 | Solid forms of a plasma kallikrein inhibitor and salts thereof | KLKB1, KLK1, KLK2 | KLKB1 1/4885CYP3A4 1270/4885CYP2C8 1744/4885 |
| US-20210171496-A1 | SOLID FORMS OF A PLASMA KALLIKREIN INHIBITOR AND SALTS THEREOF | KLKB1, KLK1, KLK2 | KLKB1 1/4885CYP3A4 1270/4885CYP2C8 1744/4885 |
| US-20230203012-A1 | SOLID FORMS OF A PLASMA KALLIKREIN INHIBITOR AND SALTS THEREOF | KLKB1, KLK1, KLK2 | KLKB1 1/4885CYP3A4 1218/4885CYP2C8 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.